Biomarker linked to prognosis in aggressive ovarian cancer

Researchers have identified a protein biomarker expressed on the surface of tumour cells in high-grade serous ovarian cancer, which is the most common and lethal subtype of the disease.

According to the Canadian scientists, from institutions including the Princess Margaret Cancer Centre (PMCC) and the University of Toronto, their findings show that patients with high levels of the biomarker CD151 have a poor prognosis.

Lead author Dr Mauricio Medrano, molecular biologist and research associate at PMCC, explained: “By identifying CD151 and its underlying role in cancer cell survival, we hope to develop a therapy to target it. As a marker for poor prognosis, with further research, there is the potential to develop a clinical screening tool to help personalise cancer treatment for patients.”

In lab experiments, the research team used cell lines derived from 40 patient tumour samples to identify that CD151 contributes to the survival of high-grade serous ovarian cancer cells. They also analysed tissue samples from approximately 1,000 patients to establish the correlation of high levels of CD151 to poor prognosis.ADNFCR-2094-ID-801833320-ADNFCR